About Somatostatin receptor type 1
Somatostatin receptor type 1 (SSTR1) is a protein
from Homo sapiens identified by UniProt accession
P30872, 391 residues long.
MolForge cross-references it against 0 known binders and
218 disease associations.
Target properties
| Protein name | Somatostatin receptor type 1 |
| UniProt accession | P30872 |
| Gene | SSTR1 |
| Organism | Homo sapiens |
| Length | 391 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (4)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (218)
Diseases linked to this target (Open Targets).
- acromegaly · score 0.60
- neoplasm · score 0.59
- neuroendocrine neoplasm · score 0.59
- carcinoid tumor · score 0.55
- digestive system neuroendocrine neoplasm · score 0.54
- carcinoid syndrome · score 0.52
- obesity · score 0.51
- cirrhosis of liver · score 0.50
- pituitary-dependent Cushing's disease · score 0.48
- esophageal varices · score 0.46
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P30872-F1 | alphafold | PREDICTED | 78.84 | — |
Amino-acid sequence (391 residues)
MFPNGTASSP SSSPSPSPGS CGEGGGSRGP GAGAADGMEE PGRNASQNGT LSEGQGSAIL ISFIYSVVCL VGLCGNSMVI YVILRYAKMK TATNIYILNL AIADELLMLS VPFLVTSTLL RHWPFGALLC RLVLSVDAVN MFTSIYCLTV LSVDRYVAVV HPIKAARYRR PTVAKVVNLG VWVLSLLVIL PIVVFSRTAA NSDGTVACNM LMPEPAQRWL VGFVLYTFLM GFLLPVGAIC LCYVLIIAKM RMVALKAGWQ QRKRSERKIT LMVMMVVMVF VICWMPFYVV QLVNVFAEQD DATVSQLSVI LGYANSCANP ILYGFLSDNF KRSFQRILCL SWMDNAAEEP VDYYATALKS RAYSVEDFQP ENLESGGVFR NGTCTSRITT L
Explore Somatostatin receptor type 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets